Biologics companies face a unique paradox. Inconsistent regulations surrounding their in-transit production one hand, and a Byzantine shipping process on the other, result in clinical delays, and ultimately potential financial losses. Streamlining the cold chain, and aligning the priorities of shippers, handlers, and legislators, are paramount, both to improve the current state of the industry and to future global healthcare.
| Have Your Say Rate this feature and give us your feedback in the comments section below |